Jump Financial, LLC Adaptimmune Therapeutics PLC Transaction History

Jump Financial, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.7 - $1.75 $47,365 - $118,413	67,665 New	67,665 $106,000
Q2 2022 Aug 09, 2022	SELL	$1.33 - $2.28 $73,948 - $126,767	-55,600 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.73 - $4.06 $108,644 - $254,967	-62,800 Reduced 53.04%	55,600 $115,000
Q4 2021 Feb 10, 2022	BUY	$3.5 - $5.68 $414,400 - $672,512	118,400 New	118,400 $444,000
Q3 2021 Nov 12, 2021	SELL	$3.44 - $6.37 $441,008 - $816,634	-128,200 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.86 - $5.78 $494,852 - $740,996	128,200 New	128,200 $546,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $195,020 - $271,834	-39,800 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.0 - $9.2 $159,200 - $366,160	39,800 New	39,800 $215,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.